S制药公司CRAM业务发展战略研究
发布时间：2018-10-26 19:53
【摘要】：医药是一个与国计民生息息相关的行业,自改革开放以来它就不断地发展壮大。作为医药行业的一个分支,小分子类化学药物的仿制在中国也呈现出蓬勃发展的趋势。S制药公司是一家专门从事该领域原料药研发与生产的企业,在行业内有一定的代表性。通过对该企业所在行业国内外发展趋势的分析,结合企业转型升级的需要,认为该企业的长期战略目标应该是研发生肽类新药,但是目前暂时没有能力去开展。因此,S制药公司近期可以采用合同研发与合同生产为主的CRAM业务模式,作为从小分子原料药仿制到生肽类新药转型升级的过渡。本论文评估了企业的外部环境,分析了企业的竞争能力,同时,结合CRAM业务的实际需求,预判了在这个过程中,S制药公司可能会遇到的问题,并给出对策,即:第一,优化职能结构;第二,建立系统的项目管理制度;第三,建立合适的内外部评估机制;第四,建立企业战略联盟。
[Abstract]:Medicine is an industry closely related to the national economy and people's livelihood. It has been developing and expanding since the reform and opening up. As a branch of the pharmaceutical industry, the imitation of small molecular chemical drugs is also showing a booming trend in China. S Pharmaceutical Company is an enterprise specializing in the research and production of API in this field, which has a certain representative in the industry. Based on the analysis of the development trend of the enterprise at home and abroad and the needs of enterprise transformation and upgrading, it is considered that the long-term strategic goal of the enterprise should be to develop new biopeptide drugs, but at present it is not able to carry out them. Therefore, S pharmaceutical company can adopt the CRAM business model of contract R & D and contract production in the near future, as the transition from small molecular raw drug imitation to biopeptide new drug transformation and upgrading. This paper evaluates the external environment of the enterprise, analyzes the competitive ability of the enterprise, at the same time, combined with the actual demand of CRAM business, predicts the problems that the S pharmaceutical company may encounter in this process, and puts forward the countermeasures: first, Optimizing the functional structure; Second, establish systematic project management system; third, establish appropriate internal and external evaluation mechanism; fourth, establish enterprise strategic alliance.
【学位授予单位】：苏州大学
【学位级别】：硕士
【学位授予年份】：2015
【分类号】：F426.72;F272
本文编号：2296785
[Abstract]:Medicine is an industry closely related to the national economy and people's livelihood. It has been developing and expanding since the reform and opening up. As a branch of the pharmaceutical industry, the imitation of small molecular chemical drugs is also showing a booming trend in China. S Pharmaceutical Company is an enterprise specializing in the research and production of API in this field, which has a certain representative in the industry. Based on the analysis of the development trend of the enterprise at home and abroad and the needs of enterprise transformation and upgrading, it is considered that the long-term strategic goal of the enterprise should be to develop new biopeptide drugs, but at present it is not able to carry out them. Therefore, S pharmaceutical company can adopt the CRAM business model of contract R & D and contract production in the near future, as the transition from small molecular raw drug imitation to biopeptide new drug transformation and upgrading. This paper evaluates the external environment of the enterprise, analyzes the competitive ability of the enterprise, at the same time, combined with the actual demand of CRAM business, predicts the problems that the S pharmaceutical company may encounter in this process, and puts forward the countermeasures: first, Optimizing the functional structure; Second, establish systematic project management system; third, establish appropriate internal and external evaluation mechanism; fourth, establish enterprise strategic alliance.
【学位授予单位】：苏州大学
【学位级别】：硕士
【学位授予年份】：2015
【分类号】：F426.72;F272
【参考文献】
相关期刊论文 前3条
1 张岚,汪恩浩;生物制药行业合同生产方式的再次兴起[J];生物工程进展;2000年01期
2 许关煜;原料药合同生产市场的现状和前景[J];上海医药;2000年10期
3 申光龙;业务外包战略的决策框架与电子制造服务[J];深圳大学学报(人文社会科学版);2001年04期
，本文编号：2296785
本文链接：https://www.wllwen.com/guanlilunwen/xiangmuguanli/2296785.html
